BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29469720)

  • 1. Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab.
    Sundaresan S; Nguyen KT; Nelson KC; Ivan D; Patel AB
    Dermatol Online J; 2017 Sep; 23(9):. PubMed ID: 29469720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe erythema exudative multiforme developing from advanced melanoma treated with dabrafenib and trametinib followed by nivolumab.
    Fujimura T; Kambayashi Y; Hidaka T; Tamabuchi E; Otake E; Tono H; Mizuashi M; Furudate S; Aiba S
    J Dermatol; 2018 Feb; 45(2):e35-e36. PubMed ID: 28983948
    [No Abstract]   [Full Text] [Related]  

  • 3. Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy.
    Nomura H; Takahashi H; Suzuki S; Kurihara Y; Chubachi S; Kawada I; Yasuda H; Betsuyaku T; Amagai M; Funakoshi T
    J Dermatol; 2017 Jul; 44(7):818-821. PubMed ID: 28295542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.
    Hofmann L; Forschner A; Loquai C; Goldinger SM; Zimmer L; Ugurel S; Schmidgen MI; Gutzmer R; Utikal JS; Göppner D; Hassel JC; Meier F; Tietze JK; Thomas I; Weishaupt C; Leverkus M; Wahl R; Dietrich U; Garbe C; Kirchberger MC; Eigentler T; Berking C; Gesierich A; Krackhardt AM; Schadendorf D; Schuler G; Dummer R; Heinzerling LM
    Eur J Cancer; 2016 Jun; 60():190-209. PubMed ID: 27085692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort.
    Hwang SJ; Carlos G; Wakade D; Byth K; Kong BY; Chou S; Carlino MS; Kefford R; Fernandez-Penas P
    J Am Acad Dermatol; 2016 Mar; 74(3):455-61.e1. PubMed ID: 26793994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
    Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Gosho M; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
    J Dermatol Sci; 2017 Nov; 88(2):225-231. PubMed ID: 28736218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
    Hwang SJE; Fernández-Peñas P
    Curr Probl Dermatol; 2018; 53():82-92. PubMed ID: 29131040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
    Mochel MC; Ming ME; Imadojemu S; Gangadhar TC; Schuchter LM; Elenitsas R; Payne AS; Chu EY
    J Cutan Pathol; 2016 Sep; 43(9):787-91. PubMed ID: 27161449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL; Patel G; Chiesa-Fuxench ZC; McGettigan S; Schuchter L; Mitchell TC; Ming ME; Chu EY
    JAMA Dermatol; 2018 Sep; 154(9):1057-1061. PubMed ID: 30027278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous Complications of Targeted Melanoma Therapy.
    de Golian E; Kwong BY; Swetter SM; Pugliese SB
    Curr Treat Options Oncol; 2016 Nov; 17(11):57. PubMed ID: 27645330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.
    Perret RE; Josselin N; Knol AC; Khammari A; Cassecuel J; Peuvrel L; Dreno B;
    Int J Dermatol; 2017 May; 56(5):527-533. PubMed ID: 28188628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel melanoma therapies and their side effects.
    González N; Ratner D
    Cutis; 2016 Jun; 97(6):426-8. PubMed ID: 27416087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report.
    Edmondson LA; Smith LV; Mallik A
    J Oncol Pharm Pract; 2017 Dec; 23(8):629-634. PubMed ID: 27609337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subclinical aortitis after starting nivolumab in a patient with metastatic melanoma. A case of drug-associated aortitis?
    Loricera J; Hernández JL; García-Castaño A; Martínez-Rodríguez I; González-Gay MÁ; Blanco R
    Clin Exp Rheumatol; 2018; 36 Suppl 111(2):171. PubMed ID: 29799390
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of immune-related adverse events and kinetics of response with ipilimumab.
    Weber JS; Kähler KC; Hauschild A
    J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Not Available].
    Mateus C; Libenciuc C; Robert C
    Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.